
Aytu BioPharma, Inc.: updates and filings
Price
$2.66
November 19, 2026Market cap $51M
What Ploutos Investor adds for Aytu BioPharma
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from FY2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 46% since Nov 16, 2026, when the 10-Q these figures come from was filed ($1.82 then, $2.66 on Nov 19, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 12, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
September 2026
May 2026
February 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026FilingFormSC TO-C
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026FORM 425Form425
- Nov 16, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Oct 27, 2026Additional annual meeting materialFormDEFA14A
- Oct 22, 2026Annual meeting proxy statementFormDEF 14A
- Sep 22, 2026Annual reportfor the period to Jun 30, 2026Form10-K
- Sep 22, 2026Results of operationsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 25, 2026Material agreement endedForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 2, 2026Material agreement entered, results of operations, unregistered sale of shares, change to shareholders' rightsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 3, 2026Quarterly reportfor the period to Dec 31, 2025Form10-Q
- Feb 3, 2026Results of operationsForm8-K
- Jan 20, 2026Regulation FD disclosureForm8-K
- Dec 10, 2025Shareholder voteForm8-K
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 13, 2025Results of operationsForm8-K
- Nov 12, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 24, 2025Annual report to shareholdersfor the period to Jun 30, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SC TO-C | Filing | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | 425 | FORM 425 | Document |
| Nov 16, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Oct 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Oct 22, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Sep 22, 2026 | 10-K | Annual reportfor the period to Jun 30, 2026 | Document |
| Sep 22, 2026 | 8-K | Results of operations | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 25, 2026 | 8-K | Material agreement ended | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 2, 2026 | 8-K | Material agreement entered, results of operations, unregistered sale of shares, change to shareholders' rights | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 3, 2026 | 10-Q | Quarterly reportfor the period to Dec 31, 2025 | Document |
| Feb 3, 2026 | 8-K | Results of operations | Document |
| Jan 20, 2026 | 8-K | Regulation FD disclosure | Document |
| Dec 10, 2025 | 8-K | Shareholder vote | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 13, 2025 | 8-K | Results of operations | Document |
| Nov 12, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 24, 2025 | ARS | Annual report to shareholdersfor the period to Jun 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 11, 2007. Of its note and share prospectuses (424B, FWP), the newest 40 of 71.
The full analysis
What do Aytu BioPharma's filings show?
The filings are where every one of Aytu BioPharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.